Imatinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Imatinib and local guidelines before prescribing.
Mechanism
BCR-ABL tyrosine kinase inhibitor.
Uses
Chronic myeloid leukaemia, GIST, Ph-positive ALL.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Fluid retention, nausea, muscle cramps, rash, myelosuppression, hepatotoxicity.
Interactions
CYP3A4 inhibitors raise levels; inducers reduce levels; warfarin interaction.
Contraindications and cautions
Severe liver impairment
Monitoring
FBC, LFT, BCR-ABL PCR
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Take with food; molecular monitoring (BCR-ABL); weight and oedema.
More from the textbook: uses, cautions and other points
- Imatinib , dasatinib, nilotinib, ponatinib (BCR-ABL tyrosine kinase) | CML , Philadelphia-positive ALL | Fluid retention, muscle cramps, rash, marrow suppression; dasatinib - pleural effusions; nilotinib - QT, vascular events; ponatinib - arterial clots; CYP3A4 interactions
Haematology: Anatomy Physiology and Pharmacology - Imatinib | CML; fluid retention, cramps; CYP3A4 interactions.
Haematology: Anatomy Physiology and Pharmacology - Imatinib / dasatinib / nilotinib / bosutinib / asciminib | CML (and Ph-positive ALL); BCR–ABL PCR monitoring; dasatinib - pleural effusions; nilotinib - vascular events, QT.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Treatment: High-dose corticosteroids; imatinib for FIP1L1-PDGFRA -positive disease; anti-IL-5 therapy (mepolizumab) in selected cases; anticoagulation for thrombus; surgery for late fibrosis or valve disease.
Cardiology: Cardiomyopathies - Interstitial cells of Cajal - the gut's pacemaker cells (origin of GIST tumours - KIT-positive, treated with imatinib).
Gastroenterology: Anatomy Physiology Pharmacology - Treated with surgery; imatinib for high-risk or advanced tumours.
Gastroenterology: Oesophagus and Stomach - Imatinib | GIST (high-risk or advanced).
Gastroenterology: Oesophagus and Stomach - Tyrosine kinase inhibitors (e.g. imatinib, ponatinib) for Philadelphia-positive ALL.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Gastroenterology: Anatomy Physiology Pharmacology (1 mention)
- Gastroenterology: Oesophagus and Stomach (2 mentions)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (4 mentions)
- Surgery: Upper GI, hepatobiliary and bariatric surgery (1 mention)
- Integrated cardiology chapter (1 mention)
- Physiology: Cells, tissues, homeostasis, fluids and acid–base balance (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)
- Cell Biology: Molecular biology, gene expression and laboratory techniques (1 mention)
- Pathology: Neoplasia - tumour biology, spread, staging and markers (2 mentions)